RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Tumor-derived type IX collagen regulates dormancy in triple-negative breast cancer cells.
Tumor-derived type IX collagen regulates dormancy in triple-negative breast cancer cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
三阴性乳腺癌(TNBC)的转移和复发主要归因于休眠癌细胞(DCCs)的存在,然而调控DCC休眠维持和再激活的分子机制仍鲜有阐明。
本研究鉴定出IX型胶原α1链(Col9a1)为TNBC休眠细胞中特异性表达的基因,并证实其是维持DCC休眠的关键分子。机制研究表明,COL9A1通过抑制FAK-AKT-p27信号轴,从而诱导G0/G1细胞周期阻滞,维持TNBC细胞休眠。敲低Col9a1可再激活DCCs,再激活的细胞通过上调视黄酸早期诱导因子1γ(RAE-1γ)并分泌促炎细胞因子(IL-15/IL-18)招募自然杀伤(NK)细胞,从而消除DCCs的免疫逃逸能力,并增强再激活TNBC细胞对多西他赛的化疗敏感性。
本研究揭示了COL9A1调控TNBC细胞休眠的新机制,表明COL9A1可作为评估TNBC休眠表型、预测肿瘤复发的潜在生物标志物,以及TNBC的新型治疗靶点。
本研究还为开发针对COL9A1的TNBC联合治疗提供了临床前证据。
Metastasis and recurrence of triple-negative breast cancer (TNBC), are mainly attributed to the presence of dormant cancer cells (DCCs), yet the molecular mechanisms governing the maintenance and reactivation of DCC dormancy remain poorly elucidated.
This study identified collagen IX alpha 1 chain (Col9a1) as a gene specifically expressed in TNBC dormant cells and confirmed that it is a key molecule sustaining DCC dormancy. Mechanistic studies revealed that COL9A1 sustains TNBC cell dormancy by suppressing the FAK-AKT-p27 signaling axis, thereby inducing G0/G1 cell cycle arrest.
Col9a1 knockdown reactivates DCCs, and the reactivated cells recruit natural killer (NK) cells by upregulating retinoic acid early inducible 1γ (RAE-1γ) and secreting proinflammatory cytokines (IL-15/IL-18), thus abrogating the immune evasion capacity of DCCs and enhancing the chemosensitivity of reactivated TNBC cells to docetaxel.
This study uncovers a novel mechanism by which COL9A1 regulates TNBC cell dormancy, indicating that COL9A1 can serve as a potential biomarker for assessing the dormant phenotype of TNBC and predicting tumor recurrence, as well as a novel therapeutic target for TNBC.
This study also provides preclinical evidence for developing COL9A1-targeted combination therapies for TNBC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。